

**THE FOLLOWING DRUGS WILL BE REVIEWED AT THE  
DRUG UTILIZATION REVIEW BOARD MEETING**

**March 18, 2014**

**Georgia Department of Community Health**

**\*This list may change at any time. If a supplemental rebate class is not listed below, the class will be reviewed at the June 5, 2014 meeting. In addition, some of the supplemental rebate classes listed below will be also be moved for review at the June 5<sup>th</sup> meeting that will be determined in February; thus, these manufacturers can present at the February Manufacturers' Forum and will not need to present again at the May Manufacturers' Forum. Please check back frequently for updates.\***

**New Drugs for Review**

Actemra<sup>®</sup> Subcutaneous

Gilotrif<sup>™</sup>

Injectafer<sup>™</sup>

Mekinist<sup>™</sup>

Olysio<sup>™</sup>

Sovaldi<sup>™</sup>

Tafinlar<sup>®</sup>

Tivicay<sup>®</sup>

**Supplemental Rebate Classes for Review**

Aminoglycosides for Cystic Fibrosis

Amphetamines

Analgesics, Opioids

Androgens-Anabolics

Antianginal Agents

Anticoagulants

Antidementia Agents

Antidiabetics, Insulins

Antidiabetics, Non-insulins

Antidiarrheals

Antiemetics

Antihemophilics

Antihistamines

Antihyperlipidemics

Antihypertensives, Angiotensin Converting Enzyme (ACE) Inhibitors

Antihypertensives, Angiotensin Receptor Blockers (ARBs)

Antihypertensives, ARB/Calcium Channel Blocker (CCB) Combinations

Antihypertensives, Beta Blockers (BBs)

Antihypertensives, Direct Renin Inhibitors

Antiinfectives, Miscellaneous

Antiinflammatory, Nonsteroidal Antiinflammatory Drugs (NSAIDs)

Antiparkinson Agents

Antivirals, Antiretrovirals

Antivirals, Hepatitis Agents

Attention Deficit Hyperactivity Disorder (ADHD) Agents

Biologic Immunomodulators

Calcium Regulators, Osteoporosis

Corticosteroids, Oral

Cough and Cold Products

Dermatologics, Antiinflammatory

Dermatologics, Antipsoriatics

Dermatologics, Corticosteroids
Dermatologics, Scabicides/Pediculocides
Digestive Enzymes
Fibromyalgia Agents
Growth Hormones
Hematopoietic Agents
Inflammatory Bowel Agents
Irritable Bowel Syndrome (IBS) Agents
Luteinizing-Hormone-Releasing Hormone (LHRH)/Gonadotropin-Releasing Hormone (GnRH) Agonist Analogs
Medical Devices for Inhaled Asthma Therapy
Migraine Agents
Multiple Sclerosis (MS) Agents
Multivitamins, Prenatal
Nasal Antiallergics
Nasal Decongestants
Nasal Steroids
Ophthalmics, Adrenergics
Ophthalmics, Antiallergics
Ophthalmics, Antiinfectives
Ophthalmics, Beta Blockers
Ophthalmics, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Ophthalmics, Prostaglandins

Ophthalmics, Steroids
Otic Antiinfectives
Phosphate Binders
Platelet Aggregate Inhibitors
Progestins
Smoking Deterrents
Ulcer Agents, Antispasmodics
Ulcer Agents, Miscellaneous
Ulcer Agents, Proton Pump Inhibitors (PPIs)
Urinary Antiinfectives
Urinary Antispasmodics
Urinary Prostatic Hypertrophy
Vaginal Antiinfectives
Vasopressors

**\*This list may change at any time. If a supplemental rebate class is not listed above, the class will be reviewed at the June 5, 2014 meeting. In addition, some of the supplemental rebate classes listed above will be also be moved for review at the June 5<sup>th</sup> meeting that will be determined in February; thus, these manufacturers can present at the February Manufacturers' Forum and will not need to present again at the May Manufacturers' Forum. Please check back frequently for updates.\***